Why the study?
Do licensed pharmacological therapies improve symptoms in adults with IBS-D or IBS-M compared to placebo?
Do licensed pharmacological therapies improve symptoms in adults with IBS-D or IBS-M compared to placebo?
Answers are grounded in this paper and cite their sources.
In a network meta-analysis, all licensed pharmacological therapies were superior to placebo for IBS-D and IBS-M, with alosetron and ramosetron appearing most effective but associated with more adverse events.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gaillard et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: